Overview

Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

Status:
Active, not recruiting

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

Summary

This study will take place in China to evaluate the safety and efficacy of OZURDEX implant 700 μg in the treatment of macular edema due to retinal vein occlusion (RVO) in patients who have never received treatment for RVO.

Phase:

Phase 4

Details

Lead Sponsor:

Allergan

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate